¿¹°©Ò©ÎïÃô¸ÐÐÔÊÔÑé,Anticancer drug sensitivity testÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« S180ϸ°û,S180 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËÔ´»¯µ¥¿Ë¡¿¹Ìå,humanized monoclonal antibodyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÔ¼¹Òº¼ì²é,Examination of cerebrospinal fluidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½þÈóºÍ×ªÒÆ,invasion and metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºÏÀíÖÎÁÆ,reasonable treatmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 15-ôÇ»ùǰÁÐÏÙËØÍÑÇâø,15-hydroxyprostaglandin dehydrogenase (15-PGDH)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈÍ´øÑùÁö,Desmoid tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ÀÁ¢×¼Ö±Æ÷,asymmetric jawsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÑºËÜÕËá΢ÕóÁÐ,oligonucleotide microarrayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹Ö×Áö¼Á(ÖÐÒ©)/ÖÎÁÆÓ¦ÓÃ,Antineoplastic agents(TCD)/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Áª¼ì,combined detectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áöϸ°ûÒßÃç,Tumor cell vaccineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶à²ãǰÏòÍøÂç,multilayer feedforward neural networksÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ªÒÆÄ£Ê½,transfer modeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹¦ÂʺÄÉ¢,Power dissipationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HSV1-TK»ùÒò,HSV1-TK geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´©Í¸Òò×Ó,penetration factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¼ÊõÖ¸ÄÏ,Technical GuideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÒÖÖÆµ°°×p53,Tumor suppressor protein p53Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈȼÁÁ¿,Thermal doseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÏÆ¤-¼äÖÊת»¯,epithelial-mesenchymal transitionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ÚÅÄ»¯ÁÆ,metronomic chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« îâ-Ñõ´ØºÏÎï,molybdenum-oxygen clusterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢Á¿ÔªËØÎø,Microelement SeleniumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò©ÎïÊäËÍϵͳ,drug delivery systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼Æ»®ÏµÍ³,planning systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »·¾³Ö°©Îï,environmental carcinogensÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿µ°¬×¢ÉäÒº,Kangai injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍíÆÚÍç¹ÌÐÔ°©Í´,Advanced refractory cancer painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊÊÐε÷Ç¿·ÅÁÆ,IMRTÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ß¾Û½ðÆÏËØ,Highly Agglutinative StaphylococcinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ªÒÆÐÔÖ×Áö,Metastatic tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×÷Óðеã,effect targetÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈýάÂ˲¨Æ÷,3-dimentional filterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûˮƽ,Cellular levelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­´úÖ×Áöϸ°û,primary cancer cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºËÌÇÌåµ°°×L11,ribosome protein L11Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸öÌ廯ҽÁÆ,Personalized medicineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ç»Éñ¾­´Ô,Celiac plexusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« B³¬Í¼Ïñ,B-mode ultrasound imageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÀÏÄêÖ×Áö»¼Õß,Aged Cancer PatientsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ªÒÆÏà¹Ø»ùÒò1,metastasis-associated gene 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« O~6-¼×»ùÄñàÑßÊ-DNA¼×»ù×ªÒÆÃ¸,O~6-methylguanine-DNA methyltransferaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹ÁöÉý°×Ƭ,Kangliu Shengbai tabletÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×¢Á¿Í¼,fluence mapÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸´·½°¢½º½¬,compound E Jiao JiangÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éý°×,leukogenic actionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ó¼ÁÁ¿¼×°±µûßÊ,high-dose methotrexateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θÃÚËØÊÍ·ÅëÄ,Gastrin-releasing peptideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖØ×éÈËP53ÏÙ²¡¶¾,recombinant human ad-p53 injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏËÈÜøԭ¼¤»îÒÖÖÆÎï1,plasminogen activator inhibitor 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ãæ²¿ÒÆÎ»Èë·,Transmaxillary approachÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Êý×ÖÖØ½¨Ó°Ïñ,digitally reconstructed radiographsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÅÆúÖÎÁÆ,abandoning treatmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÷¾×µ,sacrumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ó»ÆËØÑÜÉúÎï,emodin derivativeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖØ¸´°©,multiple primary malignant tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÀäÑ­»·Î¢²¨µ¶,transcatheter arterial chemoembolizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éϸ¹ÏÂÉñ¾­´Ô,Superior Hypogastric plexusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ͼÏñÈںϼ¼Êõ,Image Fusion TechniqueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ùÒò¶àëÄÐÔ,Gene polymorphismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñ»µ¨×ÓÓÍÈé,Brucea javanica oil emulsionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±´Àà¶àÌÇ,Shellfish polysaccharideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Äæ×ªÄÍÒ©,Reversal of multidrug-resistanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ƽºâ·¨ÐÄѪ³ØÏÔÏñ,Gated blood pool imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖØ×éÈ˰×ϸ°û½éËØ-2,RhIL-2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Cks1µ°°×,Cyclin kinase subunit 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ôÇ¿¼Íª¿ØÊÍÆ¬,Controlled-release oxycodoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÖÜÆÚµ°°×ÒÀÀµÐÔ¼¤Ã¸ÒÖÖÆ¼Á,Cyclin-dependent kinase inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©Í´ÖÎÁÆ,cancer pain managementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« δ֪ԭ·¢Ôî,unknown primaryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« patched»ùÒò,patched geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ñ£ºÛ°©,Scar cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ì岿¶ñÐÔÖ×Áö,Bodily malignant neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©Ï¸°ûÖê,cancer cell strainÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¥´¿ðåÕ¶¾ÐØÜÕ¼¤Ã¸,Herpes simplex virus thymidine kinaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ÅÐÔ±ê¼Ç,Magnetic labelingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÁÎÄ˼À¼,Evans blueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¦ÁV¦Â3ÕûºÏËØ,¦ÁV¦Â3 integrinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÃÈëÊõ,stents interventingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁªºÏ·ÅÁÆ,combination radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏËάÐÔÖ×Áö,fibrous tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÜñÂóÒȵ°°×øÒÖÖÆ¼Á,buckwheat trypsin inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µç×ÓÉäÒ°Ó°Ïñ×°ÖÃ,electronic portal imaging device (EPID)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¤¹âÓÕµ¼×ÔÌåÓ«¹â,laser induced autofluorescenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔʵÌåÖ×Áö,malignant solid tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Ö×Ó°ÐÏòÒ©Îï,Molecular Targeting DrugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÓ»¨Óê×¢ÉäÒº,xinghuayu injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Èí×éÖ¯ÏÙÅÝ×´,alveolar soft partÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« СԲϸ°ûÖ×Áö,small round cell tumorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éî¶È¼ÁÁ¿·Ö²¼,depth-dose distributionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿ÚÇ»¼ÙË¿½Íĸ¾ú,oral CandidaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Èȹà×¢»¯ÁÆ,hyperthermal perfusion chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˸ΰ©Bel-7402ϸ°û,Human hepatocellular carcinoma Bel-7402 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Numbµ°°×,Numb proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÏà¹ØÐÔÆ¶Ñª,cancer-related anemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û±£»¤¼Á,pretective agentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´Ù½áµÞ×éÖ¯ÔöÉúÐÔСԲϸ°ûÖ×Áö,desmoplastic small round cell tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶àÔ­·¢¶ñÐÔÖ×Áö,Multiple primary malignant neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
 ÉÏÒ»Ò³ 5 6 7 8 9 10 11 12 ÉÏÒ»Ò³